Navigation Links
eltrombopag in Medical News

Novel therapeutic approaches may improve patient outcomes in several platelet disorders

...l transfusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL

...ewed studies evaluating the safety and efficacy of eltrombopag in the short-term setting. Clinical data were presented and discussed that support eltrombopag increased platelet counts and reduced bleeding. ...ne Development Center at GSK. "An FDA approval for eltrombopag would represent an important development for these...

GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

...s an increased risk of bruising and bleeding.(1,2) eltrombopag is an investigational, once-daily oral treatment t...it a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. About the Data Submitted ...enna, Austria. At the end of the trial, 59% of eltrombopag treated patients on the 50mg dose and 16% of place...

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

...investigational oral platelet growth factor called eltrombopag successfully increased platelet counts and decreas...ind for ITP patients, the Phase 2 study found that eltrombopag doses of 50 and 75 mg daily elevated platelet coun... of adverse effects was similar in the placebo and eltrombopag treated groups. "These findings represent an im...

Drug May Help Reverse Clotting Deficiency

... eltrombopag might also aid patients with hepatitis liver disea... begin antiviral therapy for their condition after eltrombopag raised their platelet counts. "Eltrombopag is ...ly bleeding and bruising," Schwartz explained. eltrombopag is thought to stimulate megakaryocytes, the bone m...

GSK’s New Anticancer Drug A Huge Success In Drug trail

...y small, is likely to be transformed next year with the launch of Tykerb and other blockbuster drugs, such as the cervical cancer vaccine Cervarix and eltrombopag that is a blood-clotting agent in the treatment of breast cancer. They are also developing a lung cancer vaccine that would stop the disease from spre...
eltrombopag in Medical Technology

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

...fusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

...hKline. GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. Important Safety Information BOXED WARNI... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008; the proposed trade name ... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

...May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment ...pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea. About GlaxoSmithKline GlaxoSmit...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

...it a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008 ...se are rare.(1) About PROMACTA (eltrombopag) eltrombopag is an oral, non-peptide thrombopoietin receptor ag...ne marrow cells that give rise to blood platelets. eltrombopag was discovered as a result of research collaborati...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

...iries: Frank Murdolo 215-751-7002 Tom Curry 215-751-5419 REFERENCES (1) Bussel, JB., Cheng, G., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood. 2007; 110 (11). Published...

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

...189 patients across 135 centers in 26 countries. REPEAT (Repeat ExPosure to eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will involve 50 patient...51 5419 REFERENCES (1) Bussel, J., Provan A., Shamsi T et al. eltrombopag Raises Platelet Count and Reduces Bleeding compared with Placebo ...
eltrombopag in Biological News

Lancet study supports new, highly effective treatment for blood disorder

...ed late 2007 in the New England Journal of Medicine. This trial showed that eltrombopag was effective in raising platelet counts and lowering bleeding in adult sub...cts. Ongoing and future studies will evaluate the safety and efficacy of eltrombopag as a long-term treatment for ITP, and its efficacy and safety in population...

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

...the door to effective treatment. "In this study, eltrombopag increased platelet counts in a dose-dependent mann...common reason for a liver transplant. With other eltrombopag findings, NewYork-Presbyterian/Weill Cornell's Dr.... GlaxoSmithKline, which is developing eltrombopag. eltrombopag (marketed as Promacta in the U.S. and Revolade in ...
Other Tags
(Date:7/31/2015)... ... ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam Prep in ... The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust selection of ... easy and painless. MDLinx offers thousands of board-exam style questions and exam-specific content ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... ... 2015 , ... Creating one of the most modern fertility centers in the ... that goes beyond the boundaries of fertility medicine. , As the leading gynecology ... dependable patient support, affordable treatments, unending hope, and high fertility success rates — all ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The 2015 ... when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders Pat ... challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations to ...
(Date:7/31/2015)... ... ... The Heart Fit Clinic has increased a patient's fitness level 60 percent without ... versus 100 beats, this is a big deal," says Diamond Fernandes, director of the ... with heart disease," he adds. People with angina are able to do a lot ...
Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
Other Contents